Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company

Refine Search
Generics
An executive order by President Joe Biden has targeted anti-competitive practices in the US drugs market, including a ban of pay-for-delay agreements.   13 July 2021
Generics
US prosecutors have charged the founders of Taiwanese biosimilar manufacturer JHL Biotech with stealing Genentech trade secrets.   8 July 2021
Americas
Roche unit Spark Therapeutics is pursuing a “misguided” lawsuit that contravenes its stated mission to combat systemic racism, according to gene therapy developer Bluebird Bio.   8 July 2021
Big Pharma
Poland’s largest pharmaceutical company has asked the federal court to let it pursue arbitration in a Swiss court for a trade secrets dispute between India’s Rubicon Research and North Carolina biotech firm Kartha Pharmaceuticals.   8 July 2021
Medtech
Masimo wants to bar Apple from selling the Apple Watch Series 6, alleging the mobile manufacturer infringed five of its blood pressure monitoring patents.   6 July 2021
Generics
Teva Pharmaceuticals has filed lawsuits in New Jersey against two Indian generics manufacturers to stop them from developing a generic version of its Huntington’s disease treatment.   6 July 2021
Big Pharma
Genus claims—or patent claims covering a family of related compounds—are commonplace in life sciences patent law. But following a rising trend of invalidity rulings, the future of the claim seems bleak.   5 July 2021
Europe
The UK Government has failed to convince UK Supreme Court judges that Servier Laboratories misrepresented its blood pressure drugs patent in legal proceedings to block generic competitors from entering the market.   2 July 2021
Big Pharma
The US Supreme Court opinion in Minverva v Hologic means that inventors will now have a far narrower scope to be able to challenge the validity of their own patents in defence proceedings—a decision that was controversial among the judges.   1 July 2021
Americas
Teva and Eagle Pharmaceuticals are suing to block a generic version of its leukemia drug Bendeka, arguing its patents still have plenty of time to run.   1 July 2021